TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02752217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
Study: NCT00392704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
Study: NCT02413099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBMSI-2
Description: The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KBMSI-2
Description: The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
Study: NCT01848262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECALMIST
Description: Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InSure
Description: Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
Study: NCT03681353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management, active
Description: Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
Study: NCT01533558

Intervention type: DRUG
Intervention: caspofungin
Description: normal dosage for caspofungin, not adapted for the study
Study: NCT02689310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leptospermum scoparium honey
Description: No information available- PI left- study being withdrawn.
Study: NCT01589523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycocholic Acid
Description: 10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
Study: NCT03545178

Intervention type: BEHAVIORAL
Intervention: glucose control (Substudy A)
Description: Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device

Intervention type: DIAGNOSTIC_TEST
Intervention: hypoglycemia prediction (Substudy B)
Description: Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
Study: NCT03844178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The option for compensation of Pupil centroid shift was ON
Description: The option for compensation of Pupil centroid shift was ON

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The option for compensation of Pupil centroid shift was OFF
Description: The option for compensation of Pupil centroid shift was OFF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: installation of Tetracaine 1%
Description: installation of Tetracaine 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: installation of Tetracaine 1%
Description: installation of Tetracaine 1%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Description: periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Description: periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
Study: NCT00508859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: maintenance treatment with sertraline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04020198

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
Study: NCT02136342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorogenic acid
Study: NCT00945178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Single ascending and multiple (twice daily) oral doses, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for AZD1386
Description: Single ascending and multiple (twice daily) oral doses, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Tablet, single oral dose, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Naproxen
Description: Tablet, single oral dose
Study: NCT01997437

Intervention type: DEVICE
Group type: OTHER
Intervention: Stem-cell seeded bioartificial tracheal scaffold
Description: Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
Study: NCT01960348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patisiran (ALN-TTR02)
Description: administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: administered by intravenous (IV) infusion
Study: NCT01087749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
Study: NCT02881021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
Study: NCT02763163

Intervention type: BEHAVIORAL
Intervention: Sun exposure routine
Study: NCT02689310

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: No information available- PI left- study being withdrawn.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: No information available- PI left- study being withdrawn.
Study: NCT03461016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure \[is\] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)
Study: NCT01162148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional or regular pulmonary rehabilitation program alone
Description: Conventional or regular pulmonary rehabilitation program alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: very low load IMT (sham IMT) alone
Description: very low load IMT (sham IMT) alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
Description: Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
Study: NCT03226106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Intervention
Description: Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
Study: NCT01162148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted inspiratory resistive or threshold IMT alone
Description: Targeted inspiratory resistive or threshold IMT alone
Study: NCT01007760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke
Description: acute one time exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke
Description: acute one time exposure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke
Description: acute one time exposure
Study: NCT03226106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
Study: NCT04655183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally, once daily.
Study: NCT00618241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400 mg BD
Study: NCT02064465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Dispersible/Chewable tablet
Description: Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Compressed tablet
Description: Single dose of lamotrigine compressed 100mg tablet at Day1
Study: NCT00379431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of rituximab and methylprednisolone
Description: Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use.
Study: NCT04655183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344
Description: M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344
Description: M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344
Description: M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344
Description: M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as single agent at the approved dose.
Study: NCT01830764

Intervention type: DRUG
Group type: OTHER
Intervention: Red Light (PDT)
Description: LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)

Intervention type: DRUG
Group type: OTHER
Intervention: Red Light (PDT)
Description: LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
Study: NCT00629317

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizer
Description: Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Aminolevulinate
Description: Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
Study: NCT02230709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Needling with acupuncture needle in a myofascial trigger point.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS and dry needling
Description: Application of TENS current after dry needling technique
Study: NCT03918447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl oral capsule
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl oral capsule
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule containing an inert placebo
Study: NCT01797562

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panels 1.3, 2.2 and 3.2 experimental allergens
Description: Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
Study: NCT02185365

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.